Today: 2 February 2026
Subscribe
Browse Category

HKG:9688 News 24 December 2025 - 26 December 2025

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s That timing matters today because Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for…
26 December 2025
·····
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

December 24, 2025 — Zai Lab Limited (NASDAQ: ZLAB, HKEX: 9688) is back in the spotlight after a major regulatory catalyst in China helped lift sentiment around the biopharma name. The company announced that China’s National Medical Products Administration (NMPA) approved COBENFY (xanomeline and trospium chloride) for schizophrenia in adults—a decision that quickly rippled into trading on both its U.S.…
24 December 2025
····

Stock Market Today

  • Sportradar Group (SRAD) Share Price Weakness Highlights Valuation Debate
    February 2, 2026, 3:29 PM EST. Sportradar Group (NasdaqGS:SRAD) has posted sharp share price declines, with a 22.34% drop over one month and 29.20% over three months, despite a positive three-year shareholder return of 38.88%. Trading at $18.11, well below the $32.61 narrative fair value based on earnings and cash flow forecasts, the stock faces questions about whether recent weakness offers a buying opportunity or reflects market skepticism over growth prospects. Increased demand for real-time sports data and premium products is driving revenue of €1.23 billion and net income near €95 million, supporting optimistic forecasts. However, Sportradar's high price-to-earnings ratio of 48.1x exceeds peers and industry averages, indicating valuation risk amid market sentiment shifts. Investors weigh growth potential against competition and contract renewal uncertainties.
Go toTop